About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(CTSG-PML/RARA)135Ley
transgene insertion 135, Timothy Ley
MGI:3620013
Summary 17 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cx1
Tg(CTSG-PML/RARA)135Ley/0
Tg(CTSG-RARA/PML)#Ley/0
involves: C3H * C57BL/6 MGI:3620520
cx2
Tg(CTSG-PML/RARA)135Ley/0
Tg(CTSG-RARA/PML)2544Ley/0
involves: C3H * C57BL/6 MGI:4353301
cx3
Mleu1SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811594
cx4
Mleu2SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811884
cx5
Mleu3C57BL/6J/Mleu3SWR/J
Tg(CTSG-PML/RARA)135Ley/0
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811885
cx6
Mleu4SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811886
cx7
Mleu5SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811887
cx8
Spw1SWR/J/Spw1SWR/J
Tg(CTSG-PML/RARA)135Ley/0
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811888
cx9
Spw2SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811889
cx10
Spw3SWR/J/Spw3SWR/J
Tg(CTSG-PML/RARA)135Ley/0
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811890
cx11
Spw4SWR/J/Spw4SWR/J
Tg(CTSG-PML/RARA)135Ley/0
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811891
cx12
Spw5SWR/J/Spw5SWR/J
Tg(CTSG-PML/RARA)135Ley/0
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811892
cx13
Tg(CTSG-PML/RARA)135Ley/0
Wbcc1SWR/J/?
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811893
cx14
Tg(CTSG-PML/RARA)135Ley/0
Wbcc2SWR/J/?
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811894
cx15
Tg(CTSG-PML/RARA)135Ley/0
Wbcc3SWR/J/?
involves: C3H/HeJ * C57BL/6J * SWR/J MGI:3811895
tg16
Tg(CTSG-PML/RARA)135Ley/? involves: C3H * C57BL/6 MGI:3620517
tg17
Tg(CTSG-PML/RARA)135Ley/? Not Specified MGI:3620138


Genotype
MGI:3620520
cx1
Allelic
Composition
Tg(CTSG-PML/RARA)135Ley/0
Tg(CTSG-RARA/PML)#Ley/0
Genetic
Background
involves: C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
Tg(CTSG-RARA/PML)#Ley mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• spleens of young (< 8 mo), pre-leukemic doubly transgenic mice are significantly enlarged
• peripheral blood hemoglobin concentrations are similarly reduced in Tg(CTSG-PML/RARA)135Ley and in doubly transgenic mice with leukemia
• platelet counts are similarly diminished in Tg(CTSG-PML/RARA)135Ley and in doubly transgenic mice with leukemia
• peripheral blood WBC counts are similarly elevated in Tg(CTSG-PML/RARA)135Ley and in doubly transgenic mice with leukemia, with high proportions of early myeloid-lineage cells
• young (< 8 mo), pre-leukemic doubly transgenic mice have elevated numbers of early myeloid cells in the red pulp of the spleen

neoplasm
• 7 of 36 (19.4%) and 16 of 28 (57%) doubly transgenic mice of independent cohorts developed acute premyelocytic leukemia (APML) by 12 and 24 months of age, respectively
• the average latencies to onset of APML in two cohorts of doubly transgenic mice were 9.7 +/- 5.2 months and 12.7 +/- 3.3 months
• the proportions of early myeloid-lineage cells is similarly elevated in peripheral blood of Tg(CTSG-PML/RARA)135Ley and of doubly transgenic mice with leukemia
• an abnormal population of Gr-1+ CD34+ cells is present in bone marrow and blood of doubly transgenic mice, as of Tg(CTSG-PML/RARA)135Ley mice, with leukemia and accounts for a large proportion of leukemic spleen cells (55 +/- 13%; N=16; range 28-67%); histologic examination shows this population is enriched for immature myeloid cells
• culture of spleen cells from doubly transgenic mice with leukemia in the presence of all trans retinoic acid (ATRA) induces their differentiation to a similar extent as of splenocytes from leukemic Tg(CTSG-PML/RARA)135Ley mice

immune system
N
• Gr-1+ cells from Tg(CTSG-PML/RARA)135Ley and doubly transgenic mice with leukemia exhibit surface expression of MHC class I markers at levels similar to that of wild-type Gr-1+ spleen cells
• spleens of young (< 8 mo), pre-leukemic doubly transgenic mice are significantly enlarged
• peripheral blood WBC counts are similarly elevated in Tg(CTSG-PML/RARA)135Ley and in doubly transgenic mice with leukemia, with high proportions of early myeloid-lineage cells
• young (< 8 mo), pre-leukemic doubly transgenic mice have elevated numbers of early myeloid cells in the red pulp of the spleen

growth/size/body
• spleens of young (< 8 mo), pre-leukemic doubly transgenic mice are significantly enlarged




Genotype
MGI:4353301
cx2
Allelic
Composition
Tg(CTSG-PML/RARA)135Ley/0
Tg(CTSG-RARA/PML)2544Ley/0
Genetic
Background
involves: C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
Tg(CTSG-RARA/PML)2544Ley mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 7 of 36 (19.4%) and 16 of 28 (57%) doubly transgenic mice of independent cohorts developed acute premyelocytic leukemia (APML) b7 of 36 (19.4%) and 16 of 28 (57%) doubly transgenic mice of independent cohorts developed acute premyelocytic leukemia (APML) by 12 and 24 months of age, respectively




Genotype
MGI:3811594
cx3
Allelic
Composition
Mleu1SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mleu1SWR/J mutation (0 available); any Mleu1 mutation (0 available)
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• increased survival time after ENU-induced acute myelogenous leukemia




Genotype
MGI:3811884
cx4
Allelic
Composition
Mleu2SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mleu2SWR/J mutation (0 available); any Mleu2 mutation (0 available)
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• decreased acute myelogenous leukemia survival in animals not treated with ENU




Genotype
MGI:3811885
cx5
Allelic
Composition
Mleu3C57BL/6J/Mleu3SWR/J
Tg(CTSG-PML/RARA)135Ley/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mleu3C57BL/6J mutation (0 available); any Mleu3 mutation (0 available)
Mleu3SWR/J mutation (0 available); any Mleu3 mutation (0 available)
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• increased survival after ENU-induced acute myelogenous leukemia




Genotype
MGI:3811886
cx6
Allelic
Composition
Mleu4SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mleu4SWR/J mutation (0 available); any Mleu4 mutation (0 available)
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• decreased survival after ENU-induced acute myelogenous leukemia




Genotype
MGI:3811887
cx7
Allelic
Composition
Mleu5SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Mleu5SWR/J mutation (0 available); any Mleu5 mutation (0 available)
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• decreased acute myelogenous leukemia survival in animals not treated with ENU




Genotype
MGI:3811888
cx8
Allelic
Composition
Spw1SWR/J/Spw1SWR/J
Tg(CTSG-PML/RARA)135Ley/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Spw1SWR/J mutation (0 available); any Spw1 mutation (0 available)
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• decreased spleen weight in ENU-treated animals

immune system
• decreased spleen weight in ENU-treated animals




Genotype
MGI:3811889
cx9
Allelic
Composition
Spw2SWR/J/?
Tg(CTSG-PML/RARA)135Ley/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Spw2SWR/J mutation (0 available); any Spw2 mutation (0 available)
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• decreased spleen weight in ENU-treated animals and untreated animals

immune system
• decreased spleen weight in ENU-treated animals and untreated animals




Genotype
MGI:3811890
cx10
Allelic
Composition
Spw3SWR/J/Spw3SWR/J
Tg(CTSG-PML/RARA)135Ley/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Spw3SWR/J mutation (0 available); any Spw3 mutation (0 available)
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• increased spleen weight in animals not treated with ENU

immune system
• increased spleen weight in animals not treated with ENU

growth/size/body
• increased spleen weight in animals not treated with ENU




Genotype
MGI:3811891
cx11
Allelic
Composition
Spw4SWR/J/Spw4SWR/J
Tg(CTSG-PML/RARA)135Ley/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Spw4SWR/J mutation (0 available); any Spw4 mutation (0 available)
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• decreased spleen weight in ENU-treated animals

immune system
• decreased spleen weight in ENU-treated animals




Genotype
MGI:3811892
cx12
Allelic
Composition
Spw5SWR/J/Spw5SWR/J
Tg(CTSG-PML/RARA)135Ley/0
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Spw5SWR/J mutation (0 available); any Spw5 mutation (0 available)
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• increased spleen weight in animals not treated with ENU
• decreased spleen weight in ENU-treated animals

immune system
• increased spleen weight in animals not treated with ENU
• decreased spleen weight in ENU-treated animals

growth/size/body
• increased spleen weight in animals not treated with ENU




Genotype
MGI:3811893
cx13
Allelic
Composition
Tg(CTSG-PML/RARA)135Ley/0
Wbcc1SWR/J/?
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
Wbcc1SWR/J mutation (0 available); any Wbcc1 mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• decreased white cell count in ENU-treated animals

immune system
• decreased white cell count in ENU-treated animals




Genotype
MGI:3811894
cx14
Allelic
Composition
Tg(CTSG-PML/RARA)135Ley/0
Wbcc2SWR/J/?
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
Wbcc2SWR/J mutation (0 available); any Wbcc2 mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• increased white blood cell count in ENU-treated animals

immune system
• increased white blood cell count in ENU-treated animals




Genotype
MGI:3811895
cx15
Allelic
Composition
Tg(CTSG-PML/RARA)135Ley/0
Wbcc3SWR/J/?
Genetic
Background
involves: C3H/HeJ * C57BL/6J * SWR/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
Wbcc3SWR/J mutation (0 available); any Wbcc3 mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• increased white blood cell count in ENU-treated animals and untreated animals

immune system
• increased white blood cell count in ENU-treated animals and untreated animals




Genotype
MGI:3620517
tg16
Allelic
Composition
Tg(CTSG-PML/RARA)135Ley/?
Genetic
Background
involves: C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• spleens of young (< 8mo), pre-leukemic transgenic mice are significantly enlarged
• peripheral blood hemoglobin concentrations are reduced in transgenic mice with leukemia
• 68 +/- 7% of bone marrow cells from transgenic mice with leukemia are myelocytes or promyelocytes
• platelet counts are diminished in transgenic mice with leukemia
• transgenic mice with leukemia have elevated numbers of peripheral blood WBCs, a high proportion of them early myeloid-lineage cells
• young (< 8 mo), pre-leukemic transgenic mice have elevated numbers of early myeloid cells in the red pulp of the spleen

immune system
N
• Gr-1+ cells from transgenic mice with leukemia exhibit surface expression of MHC class I markers at levels similar to that of wild-type Gr-1+ spleen cells
• spleens of young (< 8mo), pre-leukemic transgenic mice are significantly enlarged
• transgenic mice with leukemia have elevated numbers of peripheral blood WBCs, a high proportion of them early myeloid-lineage cells
• young (< 8 mo), pre-leukemic transgenic mice have elevated numbers of early myeloid cells in the red pulp of the spleen

neoplasm
• 1 of 31 (3.2%) and 4 of 27 (15%) transgenic mice developed acute premyelocytic leukemia (APML) by 12 and 24 months of age, respectively
• the average latency to APML onset is 7.5 +/- 0.8 months
• the proportion of early myeloid-lineage cells is elevated in peripheral blood of transgenic mice with leukemia
• an abnormal population of Gr-1+ CD34+ cells is present in bone marrow and blood of transgenic mice with leukemia and accounts for a large proportion (34% and 45% in 2 animals) of leukemic spleen cells; histologic examination shows this population is enriched for immature myeloid cells
• spleen cells from transgenic mice with leukemia transmit APML resulting in death of 100% of unirradiated, syngeneic (C3H xC57BL/6)F1 mice
• culture of spleen cells from leukemic mice in the presence of all trans retinoic acid (ATRA) significantly increases the proportion of histologically identified late myeloid cells relative to those in untreated cultures

growth/size/body
• spleens of young (< 8mo), pre-leukemic transgenic mice are significantly enlarged




Genotype
MGI:3620138
tg17
Allelic
Composition
Tg(CTSG-PML/RARA)135Ley/?
Genetic
Background
Not Specified
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CTSG-PML/RARA)135Ley mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• spleens of all transgenic mice are enlarged
• transgenic mice with leukemia have massive splenomegaly
• transgenic spleens contain greatly elevated numbers of hematopoietic cells staining for the myeloid marker myeloperoxidase
• promyelocyte-specific endogenous (mouse) Ctsg mRNA is detected by RNase protection in spleens of transgenic, but not of wild-type mice
• spleens of transgenic mice with leukemia contain early-stage myeloid cells in such large numbers they disrupt the spleen architecture
• transgenic mice with leukemia may be anemic
• the bone marrow of all mice expressing this transgene is crowded with immature and mature myeloid cells
• transgenic mice with leukemia may have thrombocytopenia; however, none develop bleeding diatheses and/or disseminated intravascular coagulation
• peripheral blood counts of nonleukemic transgenic mice are normal but for a slight yet significant elevation of mature myeloid cell numbers
• the interfollicular zones (red pulp) of transgenic spleens are expanded and contain greatly elevated numbers of hematopoietic cells staining for the myeloid marker myeloperoxidase
• in transgenic mice with leukemia, the foliar architecture of the spleen is disrupted by large numbers of early-stage myeloid cells

immune system
• spleens of all transgenic mice are enlarged
• transgenic mice with leukemia have massive splenomegaly
• transgenic spleens contain greatly elevated numbers of hematopoietic cells staining for the myeloid marker myeloperoxidase
• promyelocyte-specific endogenous (mouse) Ctsg mRNA is detected by RNase protection in spleens of transgenic, but not of wild-type mice
• spleens of transgenic mice with leukemia contain early-stage myeloid cells in such large numbers they disrupt the spleen architecture
• peripheral blood counts of nonleukemic transgenic mice are normal but for a slight yet significant elevation of mature myeloid cell numbers
• the interfollicular zones (red pulp) of transgenic spleens are expanded and contain greatly elevated numbers of hematopoietic cells staining for the myeloid marker myeloperoxidase
• in transgenic mice with leukemia, the foliar architecture of the spleen is disrupted by large numbers of early-stage myeloid cells

liver/biliary system
• livers of transgenic mice with leukemia become enlarged due to accumulation of immature myeloid cells

neoplasm
• approximately 30% of transgenic mice of the 6 lines expressing the transgene eventually develop severe leukemia; the earliest cases occur at 6 months and new cases continue to occur as the mice age
• myeloid cells at various stages of differentiation account for a high proportion of peripheral blood and bone marrow cells of transgenic mice with leukemia
• S1 nuclease protection assays demonstrate expression of the transgene in peripheral blood cells of leukemic mice
• culture of splenocytes from leukemic or nonleukemic transgenic mice with all-trans retinoic acid (ATRA) reduces initially high Ctsg transcript levels to levels undetectable by S1 nuclease analysys within 2 days; clumps of undifferentiated myeloid cells present in untreated splenocyte cultures involute and are invaded by macrophages following ATRA treatment
• splenocytes from transgenic mice with leukemia reproducibly transmit the leukemic phenotype to C3.Cg-Prkdcscid mice

growth/size/body
• livers of transgenic mice with leukemia become enlarged due to accumulation of immature myeloid cells
• spleens of all transgenic mice are enlarged
• transgenic mice with leukemia have massive splenomegaly
• transgenic spleens contain greatly elevated numbers of hematopoietic cells staining for the myeloid marker myeloperoxidase
• promyelocyte-specific endogenous (mouse) Ctsg mRNA is detected by RNase protection in spleens of transgenic, but not of wild-type mice
• spleens of transgenic mice with leukemia contain early-stage myeloid cells in such large numbers they disrupt the spleen architecture





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory